news & publications

Press Releases and Articles:

8/20/2020 – TechnoVax and CUNY Med School Report COVID-19 Vaccine Breakthrough

8/19/2020 – CUNY med school, TechnoVax report COVID-19 vaccine breakthrough

9/12/2018 – TechnoVax Awarded $1.5 Million NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine

6/02/2014 – TechnoVax Awarded NIH Grant to Develop a VLP based Respiratory Syncytial Virus (RSV) Vaccine

1/08/13 – TechnoVax Awarded NIH Grant to Develop a Universal Flu Vaccine based on its Virus-Like Particle (VLP) Technology

10/20/09 – TechnoVax Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program

7/18/07 – TechnoVax Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate

12/11/06 – TechnoVax Licenses Wyeth’s Virus-Like Particle Vaccine Technology.

5/01/06 – MIT Technology Review: As it tests a new way of making vaccines, TechnoVax is targeting the deadly 1918 flu virus.

05/01/06 – MIT Technology Review: Catching the Flu: A Photo Essay.

company overview

3/20/2013 – Life Sciences & Healthcare Venture Summit – NYC

11/13/2012 – Influenza Congress – Washington DC

5/03/2012 – NYBA Annual Meeting – NYC

11/10/2011 – Influenza Congress – Washington DC (Dr. George Martin)

11/11/2011 – Influenza Congress – Washington DC (Dr. Jose Galarza)

Publications:

Clinical and Vaccine Immunology 6/2016 – Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.

Viral Immunology 2007 – A Novel Intranasal Virus-Like Particle (VLP) Vaccine Designed to Protect against the Pandemic 1918 Influenza A Virus (H1N1).

Viral Immunology 2005- Virus-Like Particle (VLP) Vaccine Conferred Complete Protection against a Lethal Influenza Virus Challenge.

Journal of Virology 2001 – Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins.